Sign in
WithdrawnNo phase

A Study in Patients With Complicated Type B Aortic Dissection Treated With the E-nya Thoracic Stent Graft

Key facts

Who runs it
JOTEC GmbH
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
25 May 2020
Ended
24 Jul 2024
Type of study
Observational
Treatments tested
  • endovascular repair
Record updated
25 July 2024
Why it stopped
Expiry of CE mark.

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Age between 18 and 85 years
  • Complicated acute, subacute or chronic type B aortic dissection with evidence of at least one of the following:; Malperfusion (visceral, renal, spinal cord and/or lower limb ischemia); Three of the following risk factors in acute or subacute dissections; Young patient; Primary entry tear > 10 mm; Early aortic expansion > 5 mm within 6 months; Total aortic diameter > 40 mm; False lumen diameter > 20 mm; Partially thrombosed false lumen; Total diameter > 50 mm in case of chronic dissections
  • Patient is hemodynamically stable (stable blood pressure and heart rate, no shock)
  • Planned proximal and distal landing zone of the E-nya Thoracic Stent Graft component(s) in the native aorta
  • Landing zone of the proximal edge of the fabric distal to the left carotid artery
  • Landing zone of the distal edge of the fabric proximal to the celiac trunk
  • Proximal landing zone diameter between 20 and 44 mm
  • Centerline distance from the distal edge of the left carotid artery to the start of the most proximal tear ≥ 20 mm
  • Thoracic aortic lesion confirmed by thin sliced (≤ 1 mm) CTA with optional three-dimensional reconstruction obtained within 3 months prior to the implant procedure
  • Patient is able and willing to undergo follow-up imaging and examinations prior to discharge from the hospital, at 30 days and 12 months, and annually thereafter until 5 years follow-up
  • Patient understands and has signed the Informed Consent Form prior to intervention whenever possible or after the intervention in case the patient's status does not allow consent to be obtained prior to intervention

Who cannot take part

  • Patients who are planned to be treated with a chimney in the left subclavian artery
  • Patients who are planned to be treated with the Petticoat concept
  • Previous stent and/or stent graft or previous surgical repair of descending thoracic aorta
  • Patient had or planned to have a major surgical or interventional procedure within 30 days before or 30 days after the planned implantation of the E-nya Stent Graft System(s). This exclusion does not include planned procedures that are needed for the safe and effective placement of the stent graft (ie, carotid/subclavian transposition, carotid/subclavian bypass procedure)
  • Genetic connective tissue diseases (e.g. Marfan Syndrome or Ehlers-Danlos Syndrome)
  • Allergies against materials necessary for endovascular repair (e.g. contrast media, heparin, materials of the stent graft)
  • Systemic or local infections
  • Myocardial infarction or cerebrovascular accident < 3 months
  • Patient has specified disease of the thoracic aorta which is not included in the registry, for example: intramural hematoma, penetrating aortic ulcer, traumatic injury or transection, (contained) aortic rupture (hemorrhage outside of aorta)
  • Other medical condition that may cause the patient to be non-compliant with the protocol, confound the results, or is associated with a limited life expectancy (i.e. heart failure, active malignancy (progressive, stable or partial remission))
  • eGFR < 45 ml/min/1.73m2 before the intervention
  • Female of child bearing potential, breast feeding
  • Access vessels not suitable for endovascular treatment
  • Significant circular thrombi or calcification in proximal or distal landing zones
  • Simultaneously participating in another clinical trial
  • NYHA class IV

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The CONFORM-TAD post-market clinical follow-up study is undertakento evaluate the prevention of death related to the treatment of a complicated acute, subacute or chronic type B aortic dissection with the E-nya Thoracic Stent Graft System. The secondary objective is to evaluate safety and clinical performance of the device.

Treatments tested

  • endovascular repair

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CONFORM-TAD- A Post-market Clinical Follow-up Study in Patients With Complicated Acute, Subacute or Chronic Type B Aortic Dissection With Double Lumen Treated With the E-nya Thoracic Stent Graft System
Record updated
25 July 2024